|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Occult hepatitis B virus infection among Egyptian blood donors显示文摘AIM:To identify blood donors with occult hepatitis B virus(HBV) infection(OBI) to promote safe blood donation.METHODS:Descriptive cross sectional study was conducted on 3167 blood donors negative for hepatitis B surface antigen(HBsAg),hepatitis C antibody(HCV Ab) and human immunodeficiency virus Ab.They were subjected to the detection of alanine aminotransferase(ALT) and aspartate transaminase(AST) and screening for anti-HBV core antibodies(total) by two different techniques;[Monoliza antibodies to hepatitis B core(Anti-HBc) Plus-Bio-Rad] and(ARC-HBc total-ABBOT).Positive samples were subjected to quantitative detection of antibodies to hepatitis B surface(anti-HBs)(ETI-AB-AUK-3,Dia Sorin-Italy).Serum anti-HBs titers > 10 IU/L was considered positive.Quantitative HBV DNA by real time polymerase chain reaction(PCR)(QIAGEN-Germany) with 3.8 IU/mL detection limit was estimated for blood units with negative serum anti-HBs and also for 32 whose anti-HBs serum titers were > 1000 IU/L.Also,265 recipients were included,34 of whom were followed up for 3-6 mo.Recipients were investigated for ALT and AST,HBV serological markers:HBsAg(ETI-MAK-4,Dia Sorin-Italy),anti-HBc,quantitative detection of anti-HBs and HBV-DNA.RESULTS:525/3167(16.6%) of blood units were positive for total anti-HBc,64% of those were antiHBs positive.Confirmation by ARCHITECT anti-HBc assay were carried out for 498/525 anti-HBc positive samples,where 451(90.6%) confirmed positive.Reactivity for anti-HBc was considered confirmed only if two positive results were obtained for each sample,giving an overall prevalence of 451/3167(14.2%) for total anti-HBc.HBV DNA was quantified by real time PCR in 52/303(17.2%) of anti-HBc positive blood donors(viral load range:5 to 3.5 x 105 IU/mL) with a median of 200 IU/mL(mean:1.8 x 104 ± 5.1 x 104 IU/mL).AntiHBc was the only marker in 68.6% of donors.Univariate and multivariate logistic analysis for identifying risk factors associated with anti-HBc and HBV-DNA positivity among blood donors showed that age above thirty and marriage were the most significant risk factors for prediction of anti-HBc positivity with AOR 1.8(1.4-2.4) and 1.4(1.0-1.9) respectively.Other risk factors as gender,history of blood transfusion,diabetes mellitus,frequent injections,tattooing,previous surgery,hospitalization,Bilharziasis or positive family history of HBV or HCV infections were not found to be associated with positive anti-HBc antibodies.Among anti-HBc positive blood donors,age below thirty was the most significant risk factor for prediction of HBV-DNA positivity with AOR 3.8(1.8-7.9).According to HBV-DNA concentration,positive samples were divided in two groups;group one with HBV-DNA ≥ 200 IU/mL(n = 27) and group two with HBV-DNA < 200 IU/mL(n = 26).No significant difference was detected between both groups as regards mean age,gender,liver enzymes or HBV markers.Serological profiles of all followed up blood recipients showed that,all were negative for the studied HBV markers.Also,HBV DNA was not detected among studied recipients,none developed post-transfusion hepatitis(PTH) and the clinical outcome was good.CONCLUSION:OBI is prevalent among blood donors.Nucleic acid amplification/HBV anti core screening should be considered for high risk recipients to eliminate risk of unsafe blood donation. | Zeinab N Said Manal H El Sayed Iman I Salama Enas K Aboel-Magd Magda H Mahmoud Maged El Setouhy Faten Mouftah Manal B Azzab Heidi Goubran Amal Bassili Gamal E Esmat | 2013 | World Journal of Hepatology2013，5，2： | 4 |
| 2 | Rabeprazol in treatment of acid peptic disease:results of three placebo - controlled dose - response clinical trials in duodenal ulcer , gastric ulcer and gastroesphageal reflux disease (GERD) 显示文摘 | Cloud ML Enas N Humphries TJ | 1998 | Dig Dis Sci1998，43，： | 1 |
| 3 | Rabeprazol in treatment of acid peptic disease:results of three piacebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer and GERD显示文摘 | Cloud ML Enas N Humphries TJ | 1998 | Dig Dis Sci1998，43，5： | 1 |
| 4 | Catalytic activity of baker's yeast in a mediatorless microbial fuel cell显示文摘 | ENAS T S TAKUYA T NOBUYOSHI N | 2012 | Bioelectroehemistry2012，86，： | 1 |
| 5 | An investigational new drug treatment program for patients with gemcitabine:results for over 3000 patients with pancreatic carcinoma显示文摘 | Storniolo A M Enas N H Brown C A | 1999 | Cancer1999，85，6： | 1 |
| 6 | Changes in proteins and tenderness of meat from young bulls of forr breeds at three ages over 10 days of cold storage显示文摘 | Agnieszka Iwanowska Ewa Iwa(n)ska Bo(z)ena Grze o | | 0，，1： | 1 |
| 7 | High prevalence of microproteinuria,an early index of renal impainment in patients with diffuse psoriasis显示文摘 | MABEDDU P ENA P GLORIOSO N | 1988 | Nephron1988，48，3： | 1 |
| 8 | Aninvestigational new drug treatment program for patients with gemcitabine:results for over 3000 patients with pancreatic carcinoma显示文摘 | STORNIOLO A M ENAS N H BROWN C A | 1999 | Cancer1999，85，6： | 1 |
| 9 | Rabeprazole in treatment of acid pptic diseases:results of three placebo-controlled dose-response clinical trials in duodenal ulcer,gastric ulcer and gastroesophageal reflux disease (GERD)显示文摘 | CLOUD ML ENAS N HUMPHRIES TJ | 1998 | Dig Dis Sci1998，43，5： | 1 |
| 10 | An investigational newdrug treatment programfor patients with gemcitabine: results for over 3 000 patients with pancreatic carcinoma 显示文摘 | Storniolo A M Enas N H Brown C A | 1999 | Cancer1999，85，： | 1 |
| 11 | An investigation new drug treatment program for patients with gemcitabine:results for over 3000 patients with pancreatic carcinoma显示文摘 | STORNIOLO A M ENAS N H BROWN C A | 1999 | Cancer1999，85，6： | 1 |
| 12 | High prevalence of microproteinuria,an early index of renal impairnent, in patients with diffuse psoriasis 显示文摘 | Madedda P Ena P Glorioso N | 1988 | Nephron1988，48，3： | 1 |
| 13 | Quantum bi-Hamiltonian systems显示文摘 | Cari(n)ena J Grabowski J Marmo G | | 0，，： | 1 |
| 14 | An investigational newdrug treatment programfor patients with gemcitabine:results for over 3000 patients with pancreatic carcinoma显示文摘 | Storniolo A M Enas N H Brown C A | 1999 | Cancer1999，87，85： | 1 |
| 15 | High prevalence of microproteinuria,an early index of renal impairment,in patients with diffuse psoriasis显示文摘 | Madeddu P Ena P Glorioso N | 1988 | Nephron1988，48，3： | 1 |
| 16 | An investigation news drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma显示文摘 | Storniolo A M Enas N H Brown C A | 1999 | Cancer1999，85，6： | 1 |
| 17 | Rabeprazole in treatment of acid peptic diseases (results of three placebo-con- trolled dose-response clinical trials in duodenal ulcer, gastric ul- cer, and gastroesophageal reflux disease (GERD) 显示文摘 | Cloud M L Enas N Humphries T J | 1998 | Diges- tive diseases and sciences1998，43，5： | 1 |
| 18 | High prevalence of microprotrinuria,an early index of renal impaiment,in patients with diffuse psoriasis显示文摘 | Ena P Glorioso N | 1988 | Nephron1988，48，： | 1 |
| 19 | Pharmacodynamic trial of nimo-tuzumab in unresectable squamous cel carcinoma of the head and neck:a sendo foundation study显示文摘 | Rojo F Gracias E Vil ena N | | 0，，08： | 1 |
| 20 | Immobilized Inulinase on Grafted Alginate Beads Prepared bythe One-Step and the Two-Steps Methods 显示文摘 | Enas N DaniaU Magdy M M Elnashar Ghada E A A wad | 2010 | Industrial and Engineering Chemistry Research2010，49，31： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员